ROBOTICS & AUTOMATION
Empowering Progress
Up to 25% off Essentials Robotics and Automation titles
Medicines for Cancer
Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies
- 1st Edition - April 18, 2023
- Author: Surya K. De
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 1 2 - 1
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 5 2 1 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 3 1 3 - 8
Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies covers most known anti-cancer therapeutics. Cancer is the se… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteMedicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies covers most known anti-cancer therapeutics. Cancer is the second leading cause of death worldwide, with its various forms resulting in nearly one out of every six mortalities each year. This book describes all US FDA-approved drugs (up to 2021), such as small molecules, peptides, monoclonal antibodies, whole antibodies, gene therapy, antibody-drug conjugates, cell therapy, and immunotherapies, along with information on their generic and brand names, medical uses, details dosage, mechanisms of actions, pharmacokinetics and side effects. Chemical structures of small molecules, small peptides, antibody-drug conjugates are also provided.
This book is ideal for medicinal chemists, oncologists, and pharmacologists, but it will also be indispensable for professional researchers, whether they are working in the clinic or the pharmaceutical industry.
- Covers precise information on each drug treatment
- Catalogues and lists all FDA-approved drugs for cancer group by chemical classes
- Provides easy access to specific drugs
Researchers and postgraduate students in Medicinal Chemistry, Pharmacology, and other cancer-related fields. Oncologists and medical research professionals
- Cover image
- Title page
- Table of Contents
- Copyright
- Medical advice disclaimer
- About the author
- Preface
- Common abbreviations and acronyms
- Chapter 1. Drug nomenclature
- 1.1. Generic formula
- Chapter 2. Chemotherapy
- 2.1. Alkylating antineoplastic agents
- 2.2. Nitrosoureas
- 2.3. Antimetabolites
- 2.4. Antitumor antibiotics
- 2.5. Topoisomerase inhibitors
- 2.6. Mitotic inhibitors (antimicrotubule agents)
- 2.7. Corticosteroids
- 2.8. Other chemotherapy drugs
- 2.9. US FDA-approved current chemotherapy agents
- 2.10. Albumin-bound paclitaxel
- 2.11. Amifostine
- 2.12. Arsenic trioxide
- 2.13. Asparaginase Erwinia chrysanthemi
- 2.14. Azacitidine
- 2.15. Bendamustine
- 2.16. Bleomycin
- 2.17. Busulfan
- 2.18. Cabazitaxel
- 2.19. Calaspargase pegol-mknl
- 2.20. Capecitabine
- 2.21. Carboplatin
- 2.22. Carmustine
- 2.23. Chlorambucil
- 2.24. Cisplatin
- 2.25. Cladribine
- 2.26. Clofarabine
- 2.27. Cyclophosphamide
- 2.28. Cytarabine
- 2.29. Dacarbazine
- 2.30. Dactinomycin
- 2.31. Daunorubicin
- 2.32. Decitabine
- 2.33. Dexamethasone
- 2.34. Docetaxel
- 2.35. Doxorubicin
- 2.36. Doxorubicin liposome
- 2.37. Epirubicin
- 2.38. Eribulin mesylate
- 2.39. Etoposide
- 2.40. Fludarabine
- 2.41. 5-Fluorouracil
- 2.42. Gemcitabine
- 2.43. Hydroxyurea
- 2.44. Idarubicin
- 2.45. Ifosfamide
- 2.46. Irinotecan
- 2.47. Ixabepilone
- 2.48. Lomustine
- 2.49. Lurbinectedin
- 2.50. Lutetium Lu 177-dotatate
- 2.51. Mechlorethamine
- 2.52. Melphalan
- 2.53. Mercaptopurine
- 2.54. Methotrexate
- 2.55. Mitomycin-C
- 2.56. Mitoxantrone
- 2.57. Nelarabine
- 2.58. Oxaliplatin
- 2.59. Paclitaxel
- 2.60. Pemetrexed
- 2.61. Pralatrexate
- 2.62. Procarbazine
- 2.63. Radium 223 dichloride
- 2.64. Temozolomide
- 2.65. Thioguanine
- 2.66. Thiotepa
- 2.67. Topotecan
- 2.68. Trabectedin
- 2.69. Valrubicin
- 2.70. Vinblastine
- 2.71. Vincristine
- 2.72. Vinorelbine
- Chapter 3. Hormonal therapy
- 3.1. Abiraterone acetate
- 3.2. Anastrozole
- 3.3. Apalutamide
- 3.4. Bicalutamide
- 3.5. Darolutamide
- 3.6. Degarelix
- 3.7. Enzalutamide
- 3.8. Exemestane
- 3.9. Flutamide
- 3.10. Fulvestrant
- 3.11. Goserelin
- 3.12. Lanreotide
- 3.13. Letrozole
- 3.14. Leuprolide (Leuprorelin)
- 3.15. Megestrol acetate
- 3.16. Nilutamide
- 3.17. Raloxifene
- 3.18. Relugolix
- 3.19. Tamoxifen
- 3.20. Toremifene
- Chapter 4. Targeted therapy: small molecules
- 4.1. Small molecules
- 4.2. Small molecules as targeted therapy
- 4.3. Abemaciclib
- 4.4. Acalabrutinib
- 4.5. Afatinib
- 4.6. Alectinib
- 4.7. Alpelisib
- 4.8. Avapritinib
- 4.9. Axitinib
- 4.10. Belinostat
- 4.11. Bexarotene
- 4.12. Binimetinib
- 4.13. Bortezomib
- 4.14. Bosutinib
- 4.15. Brigatinib
- 4.16. Cabozantinib
- 4.17. Capmatinib
- 4.18. Carfilzomib
- 4.19. Ceritinib
- 4.20. Cobimetinib
- 4.21. Copanlisib
- 4.22. Crizotinib
- 4.23. Dabrafenib
- 4.24. Dacomitinib
- 4.25. Dasatinib
- 4.26. Enasidenib
- 4.27. Encorafenib
- 4.28. Entrectinib
- 4.29. Erdafitinib
- 4.30. Erlotinib
- 4.31. Everolimus
- 4.32. Fedratinib
- 4.33. Fostamatinib
- 4.34. Gefitinib
- 4.35. Gilteritinib
- 4.36. Glasdegib
- 4.37. Ibrutinib
- 4.38. Idelalisib
- 4.39. Imatinib
- 4.40. Imiquimod
- 4.41. Infigratinib
- 4.42. Iobenguane I 131
- 4.43. Ivosidenib
- 4.44. Ixazomib
- 4.45. Lapatinib
- 4.46. Larotrectinib
- 4.47. Lenalidomide
- 4.48. Lenvatinib
- 4.49. Lorlatinib
- 4.50. Midostaurin
- 4.51. Mobocertinib
- 4.52. Neratinib
- 4.53. Nilotinib
- 4.54. Niraparib
- 4.55. Olaparib
- 4.56. Omacetaxine mepesuccinate
- 4.57. Osimertinib
- 4.58. Palbociclib
- 4.59. Pazopanib
- 4.60. Pemigatinib
- 4.61. Pexidartinib
- 4.62. Pomalidomide
- 4.63. Ponatinib
- 4.64. Pralsetinib
- 4.65. Regorafenib
- 4.66. Ribociclib
- 4.67. Ripretinib
- 4.68. Romidepsin
- 4.69. Rucaparib
- 4.70. Selinexor
- 4.71. Selpercatinib
- 4.72. Selumetinib
- 4.73. Sonidegib
- 4.74. Sorafenib
- 4.75. Sunitinib
- 4.76. Talazoparib
- 4.77. Tazemetostat
- 4.78. Temsirolimus
- 4.79. Tepotinib
- 4.80. Thalidomide
- 4.81. Tivozanib
- 4.82. Trametinib
- 4.83. Tucatinib
- 4.84. Umbralisib
- 4.85. Vandetanib
- 4.86. Vemurafenib
- 4.87. Venetoclax
- 4.88. Vismodegib
- 4.89. Vorinostat
- 4.90. Zanubrutinib
- 4.91. Pharmacokinetics
- 4.92. Zoledronic acid
- Chapter 5. Targeted therapy: monoclonal antibody
- 5.1. Alemtuzumab
- 5.2. Amivantamab
- 5.3. Bevacizumab
- 5.4. Cetuximab
- 5.5. Daratumumab
- 5.6. Ibritumomab tiuxetan
- 5.7. Isatuximab-irfc
- 5.8. Margetuximab-cmkb
- 5.9. Mogamulizumab-kpkc
- 5.10. Naxitamab-gqgk
- 5.11. Necitumumab
- 5.12. Obinutuzumab
- 5.13. Ofatumumab
- 5.14. Panitumumab
- 5.15. Pertuzumab
- 5.16. Ramucirumab
- 5.17. Rituximab
- 5.18. Tafasitamab
- 5.19. Tagraxofusp
- 5.20. Trastuzumab
- Chapter 6. Targeted therapy: antibody–drug conjugate
- 6.1. Ado-trastuzumab emtansine
- 6.2. Belantamab mafodotin-blmf
- 6.3. Brentuximab vedotin
- 6.4. Enfortumab vedotin-ejfv
- 6.5. Fam-trastuzumab deruxtecan-nxki
- 6.6. Gemtuzumab ozogamicin
- 6.7. Inotuzumab ozogamicin
- 6.8. Loncastuximab tesirine-lpyl
- 6.9. Polatuzumab vedotin-piiq
- 6.10. Sacituzumab govitecan-hziy
- 6.11. Tisotumab vedotin-tftv
- Chapter 7. Immunotherapy
- 7.1. Types of immunotherapies
- 7.2. Aldesleukin
- 7.3. Atezolizumab
- 7.4. Avelumab
- 7.5. Axicabtagene ciloleucel
- 7.6. Blinatumomab
- 7.7. Brexucabtagene autoleucel
- 7.8. Cemiplimab-rwlc
- 7.9. Denileukin diftitox
- 7.10. Dinutuximab
- 7.11. Dostarlimab-gxly
- 7.12. Durvalumab
- 7.13. Elotuzumab
- 7.14. Idecabtagene vicleucel
- 7.15. Ipilimumab
- 7.16. Lisocabtagene maraleucel
- 7.17. Moxetumomab pasudotox-tdfk
- 7.18. Nivolumab
- 7.19. Pembrolizumab
- 7.20. Sipuleucel-T
- 7.21. Talimogene laherparepvec
- 7.22. Tisagenlecleucel
- Chapter 8. Drugs approved for different types of cancer
- 8.1. Generic and brand names of approved medicines for cancer
- 8.2. Drugs approved for anal cancer
- 8.3. Drugs approved to prevent anal cancer
- 8.4. Drugs approved for bladder cancer
- 8.5. Drug combinations used in bladder cancer
- 8.6. Drugs approved for bone cancer
- 8.7. Drugs approved for brain tumors
- 8.8. Drug combinations used in brain tumors
- 8.9. Drugs approved for breast cancer
- 8.10. Drug combinations used in breast cancer
- 8.11. Drugs approved to prevent breast cancer
- 8.12. Drugs approved to treat cervical cancer
- 8.13. Drug combinations used in cervical cancer
- 8.14. Drugs approved to prevent cervical cancer
- 8.15. Drugs approved for colon and rectal cancer
- 8.16. Drug combinations used in colon and rectal cancer
- 8.17. Drugs approved for endometrial cancer
- 8.18. Drug combinations used in endometrial cancer
- 8.19. Drugs approved for esophageal cancer
- 8.20. Drug combinations used in esophageal cancer
- 8.21. Drugs approved for gastrointestinal stromal tumors
- 8.22. Drugs approved for gastroesophageal junction cancer
- 8.23. Drugs approved for gestational trophoblastic disease
- 8.24. Drugs approved for head and neck cancer
- 8.25. Drug combinations used in head and neck cancer
- 8.26. Drugs approved for hodgkin lymphoma
- 8.27. Drug combinations used in hodgkin lymphoma
- 8.28. Drugs approved for kaposi sarcoma
- 8.29. Drugs approved for renal cell carcinoma (RCC)
- 8.30. Drugs approved for upper tract urothelial cancer (UTUC)
- 8.31. Drugs approved for wilms tumor and other childhood kidney cancers
- 8.32. Drugs approved for acute lymphocytic leukemia (ALL)
- 8.33. Drug combinations used in acute lymphocytic leukemia (ALL)
- 8.34. Drugs approved for acute myeloid leukemia (AML)
- 8.35. Drug combinations used in acute myeloid leukemia (AML)
- 8.36. Drugs approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- 8.37. Drugs approved for chronic lymphocytic leukemia (CLL)
- 8.38. Drug combinations used in chronic lymphocytic leukemia (CLL)
- 8.39. Drugs approved for chronic myelogenous leukemia (CML)
- 8.40. Drugs approved for hairy cell leukemia
- 8.41. Drugs approved for mast cell leukemia
- 8.42. Drugs approved for meningeal leukemia
- 8.43. Drugs approved for liver cancer
- 8.44. Drugs approved for non-small cell lung cancer
- 8.45. Drug combinations used to treat non-small cell lung cancer
- 8.46. Drugs approved for small cell lung cancer
- 8.47. Drugs approved for malignant mesothelioma
- 8.48. Drug combinations used in malignant mesothelioma
- 8.49. Drugs approved for multicentric castleman disease
- 8.50. Drugs approved for multiple myeloma and other plasma cell neoplasms
- 8.51. Drug combinations used in multiple myeloma and other plasma cell neoplasms
- 8.52. Drugs approved for myeloproliferative neoplasms
- 8.53. Drug combinations used in myeloproliferative neoplasms
- 8.54. Drugs approved for neuroblastoma
- 8.55. Drug combinations used in neuroblastoma
- 8.56. Drugs approved for non-hodgkin lymphoma
- 8.57. Drug combinations used in non-hodgkin lymphoma
- 8.58. Drugs approved for ovarian, fallopian tube, or primary peritoneal cancer
- 8.59. Drug combinations used in ovarian, fallopian tube, or primary peritoneal cancer
- 8.60. Drugs approved for pancreatic cancer
- 8.61. Drug combinations used in pancreatic cancer
- 8.62. Drugs approved for gastroenteropancreatic neuroendocrine tumors
- 8.63. Drugs approved for pancreatic neuroendocrine tumors
- 8.64. Drugs approved for penile cancer
- 8.65. Drugs approved for pheochromocytoma
- 8.66. Drugs approved for paraganglioma
- 8.67. Drugs approved for prostate cancer
- 8.68. Drugs approved for retinoblastoma
- 8.69. Drug combinations used in retinoblastoma
- 8.70. Drugs approved for rhabdomyosarcoma
- 8.71. Drugs approved for basal cell carcinoma
- 8.72. Drugs approved for cutaneous squamous cell carcinoma
- 8.73. Drugs approved for merkel cell carcinoma
- 8.74. Drugs approved for melanoma
- 8.75. Drugs approved for soft tissue sarcoma
- 8.76. Drug combinations used in soft tissue sarcoma
- 8.77. Drugs approved to treat solid tumors anywhere in the body
- 8.78. Drugs approved for stomach (gastric) cancer
- 8.79. Drug combinations used in stomach (gastric) cancer
- 8.80. Drugs approved for gastroenteropancreatic neuroendocrine tumors
- 8.81. Drugs approved for testicular cancer
- 8.82. Drug combinations used in testicular cancer
- 8.83. Drugs approved for thyroid cancer
- 8.84. Drugs approved for vaginal cancer
- 8.85. Drugs approved to prevent vaginal cancer
- 8.86. Drugs approved to treat vulvar cancer
- 8.87. Drugs Approved to prevent vulvar cancer
- Index
- No. of pages: 632
- Language: English
- Edition: 1
- Published: April 18, 2023
- Imprint: Elsevier
- Paperback ISBN: 9780443133121
- eBook ISBN: 9780443285219
- eBook ISBN: 9780443133138
SD
Surya K. De
Dr De holds fifteen United States and international patents. Due to his abundant research contributions in the areas of cancer, metabolic diseases, organic and medicinal chemistry, and neuroscience, he has earned the distinction of Fellow of the Royal Society of Chemistry in 2010, and was subsequently awarded the status of Chartered Chemist in 2011. He is an elected Councilor in the American Chemical Society (San Diego section). He is editorial board member of Anticancer Agents in Medicinal Chemistry and Current Organic Synthesis.
Affiliations and expertise
American Chemical Society, San Diego, USARead Medicines for Cancer on ScienceDirect